SAN DIEGO, Jan. 20, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the steering committee of ENDO 2015 has selected the abstract of their recently completed clinical study of NBI-77860 in classic congenital adrenal hyperplasia for an oral presentation on the initial day of the Endocrine Society's 97th Annual Meeting. ENDO is the world's largest endocrinology meeting drawing over 10,000 experts from around the world. The ENDO 2015 meeting will be held in San Diego from March 5-8, 2015.
"We are pleased to have been selected to hold an oral presentation at the annual meeting of the Endocrine Society and to share the clinical data of NBI-77860 in classic congenital adrenal hyperplasia with the broader scientific community," said Chris O'Brien, M.D., Chief Medical Officer at Neurocrine. "Congenital adrenal hyperplasia is a disease with a significant unmet medical need and NBI-77860 may potentially make an important difference in patients' lives. The ENDO annual meeting brings together the world's thought leaders in endocrinology to discuss the latest advances in the field and we look forward to discussing our clinical results at this meeting."
The oral presentation of the results from the initial clinical study of NBI-77860 for the treatment of classic congenital adrenal hyperplasia will occur at the 97th Annual Meeting of the Endocrine Society on Thursday, March 5, 2015 from 11:30 am to 1:00 pm (PST). The session is entitled "HPA Axis and Adrenal: Receptors to Clinical Impact."
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.
In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, and Company overall. In addition, the Company faces risks and uncertainties with respect to the Company's R & D pipeline including risk that the Company's clinical candidates will not be found to be safe and effective; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2013 and on Form 10-Q for each of the quarters ended March 31, 2014, June 30, 2014 and September 30, 2014. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.
SOURCE Neurocrine Biosciences, Inc.